BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years - PubMed

BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov